RxDoctor Payments Data

Peter Gottesfeld, MD

Family Medicine · Yorktown Heights, NYNPI 1114011368

Payments from drug & device makers

$16,591in general payments, 2019–2025

Across 288 payments — averaging $57.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$14K
  • AbbVie$617
  • Amgen$526
  • Novo Nordisk$279
  • AstraZeneca$236
  • Kowa Pharmaceuticals America, Inc.$209
  • plus $764 from 12 others

What the payments were for

  • Speaking & faculty fees$8,12049%
  • Travel & lodging$3,28620%
  • Food & beverage$5,13931%
  • Education$470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,591 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$124,467
Medicare patients
203
Services billed
1,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$58,336
OzempicSemaglutide32$52,990
BiktarvyBictegrav/Emtricit/Tenofov Ala12$46,819
VascepaIcosapent Ethyl42$38,837
MounjaroTirzepatide17$28,001
LinzessLinaclotide28$26,470
WegovySemaglutide20$25,489
Repatha SureclickEvolocumab28$24,605
XareltoRivaroxaban12$15,029
LivaloPitavastatin Calcium12$9,568
Rosuvastatin Calcium254$4,144
Oxycodone Hcl60$3,312
Pitavastatin Calcium14$3,126
SynthroidLevothyroxine Sodium37$2,940
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen68$2,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$279$78,47952 claims
AbbVieLinzess, Synthroid$617$29,41065 claims
Lilly USA, LLCMounjaro$107$28,00117 claims
Johnson & JohnsonXarelto$38$15,02912 claims
Kowa Pharmaceuticals America, Inc.Livalo$209$9,56812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Yorktown Heights

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →